Valor Compounding Pharmacy plans first CME webinar on BHRT

Valor Compounding Pharmacy will host its first CME-certified webinar on bioidentical hormone replacement therapy on Sept. 30, 2026, with free registration and optional CME credit for licensed healthcare providers. The Berkeley pharmacy says the session is meant to give prescribers a practical framework for evaluating, initiating and managing BHRT.

Why it matters: - The webinar gives licensed healthcare providers a CME-certified way to learn about bioidentical hormone replacement therapy, a topic that is drawing growing attention in patient care. - The session is aimed at helping prescribers make more informed decisions about compounded hormone options, which are not FDA-approved. - The training may be especially useful for clinicians in integrative medicine, functional medicine, women’s health and endocrinology-focused care.

What happened: - Valor Compounding Pharmacy announced its first continuing medical education webinar, “Bioidentical Hormone Replacement Therapy (BHRT): An Introductory Guide for Prescribers.” - The live webinar is scheduled for Wednesday, Sept. 30, 2026, from 10:00 a.m. to 11:15 a.m. PST, or 1:00 p.m. to 2:15 p.m. EST. - The event is free to attend. - Licensed physicians, nurse practitioners, physician associates and other healthcare providers can register. - Providers can add CME credit during registration for a one-time $99 fee. - Registration is available now at Valor's CME webinar page.

The details: - Valor is a multi-state licensed 503A compounding pharmacy based in Berkeley, California. - The company describes itself as one of a small number of compounding pharmacies offering CME-certified training for prescribers. - The webinar is designed for providers who are new to BHRT or want to revisit the fundamentals. - Christine Stephanos, RPh, BCSCP, Valor’s vice president and chief pharmacy officer, will lead the session. - The agenda includes endogenous hormone pathways relevant to menopausal and perimenopausal care. - The session will cover how compounded BHRT differs from FDA-approved hormone therapy in evidence and regulatory status. - The program will address the current regulatory landscape for hormone therapy and compounded preparations. - The webinar will include guidance on interpreting laboratory testing for individualized treatment decisions. - The session will also examine clinical factors providers consider when deciding whether a compounded formulation may be appropriate for a patient. - The program ends with 15 minutes of live Q&A. - CME Outfitters, LLC is jointly accredited by the ACCME, ACPE and ANCC to provide continuing education for the healthcare team. - CME Outfitters designates the live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. - Christine Stephanos has nothing to disclose. - Planning committee members Daniela Jones, Marie Judkins, Shari Tordoff and Imman Rathore have nothing to disclose. - All relevant financial relationships have been mitigated. - The activity may discuss products or devices not currently labeled for FDA use. - CME Outfitters, the faculty and Valor do not endorse use outside FDA-labeled indications. - The educational activity is for licensed healthcare professionals only and is for educational purposes, not medical, legal or regulatory advice. - Clinical decisions should be based on independent professional judgment and applicable laws and guidelines. - Compounded medications are not FDA-approved and have not been evaluated by the U.S. Food and Drug Administration for safety or effectiveness.

Between the lines: - Valor is pairing provider education with its core business as a compounding pharmacy, which can help build trust with prescribers who are trying to navigate a complicated and often debated treatment area. - The CME format suggests the company is positioning the webinar as professional education rather than marketing. - The focus on regulatory distinctions and lab interpretation points to the main barrier many clinicians face in BHRT: how to weigh individualized treatment against limited consensus and oversight differences.

What's next: - Providers can register now, and space is limited. - Those who want CME credit must select it during registration and pay the additional $99 fee. - The live Q&A may surface the practical questions clinicians are most likely to carry into real-world prescribing decisions. - Valor says it offers provider education to support licensed clinicians in their independent decision-making, suggesting more training could follow.